Reports Q1 revenue $88.71M, consensus $86.95M. “We ended the first quarter of fiscal 2025 with our eighth consecutive quarter of revenue growth and continued improvement in gross margin. We’re starting the fiscal year strong, demonstrating our unwavering commitment to progressing toward adjusted EBITDA breakeven,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST).
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio